Scientific publications

Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma

Jul 1, 2019 | Magazine: Journal of Vascular and Interventional Radiology

Vivas I (1), Iribarren K (2), Lozano T (2), Cano D (1), Lasarte-Cia A (2), Chocarro S (2), Gorraiz M (2), Sarobe P (2), Hervás-Stubbs S (2), Bilbao JI (1), Casares N (3), Lasarte JJ (2).


Mice and rabbits bearing hepatocellular carcinoma tumors (Hepa.129 and VX2 tumor models, respectively) were treated with IRE (2 pulses of 2500V), with poly-ICLC, or with IRE + poly-ICLC combination therapy. Tumor growth in mice was monitored using a digital caliper and by computed tomography in rabbits.


Intratumoral administration of poly-ICLC immediately before IRE elicited shrinkage of Hepa.129 cell-derived tumors in 70% of mice, compared to 30% and 26% by poly-ICLC or IRE alone, respectively (P = .0004). This combined therapy induced the shrinkage of VX-2-based hepatocellular carcinoma tumors in 40% of rabbits, whereas no response was achieved by either individual treatment (P = .045). The combined therapy activated a systemic antitumor response able to inhibit the growth of other untreated tumors.


IRE treatment, immediately preceded by the intratumoral administration of an immunogenic adjuvant such as poly-ICLC, might enhance the antitumor effect of the IRE procedure. This combination might facilitate the induction of a long-term systemic response to prevent tumor relapses and the appearance of metastases.

CITATION  J Vasc Interv Radiol. 2019 Jul;30(7):1098-1105.
doi: 10.1016/j.jvir.2019.02.023. Epub 2019 May 14.

Our authors

Dr. Teresa Lozano Moreda
Researcher | Principal Investigator Immunology and Immunotherapy Research Program
Aritz Lasarte Cía
Marta Gorraiz Ayala
Dr. Sandra Hervás Stubbs
Researcher | Principal Investigator Adoptive Cell Therapy Research Group